



# Biotech Daily

Thursday June 24, 2021

*Daily news on ASX-listed biotechnology companies*

- \* **ASX DOWN, BIOTECH UP: RESONANCE UP 13%; PRESCIENT DOWN 11%**
- \* **PATRY'S TELLS ASX: 'JOURNAL EMBARGOED DESPITE 21% PRICE JUMP'**
- \* **LABCON PAYS BLUECHIIP \$2.1m FOR RESOLUTION; NEW DEAL**
- \* **NEXT SCIENCE, ZIMMER TALKS ON XPERIENCE DISTRIBUTION**
- \* **PRESCIENT: OMNICAR PARTS MANUFACTURE COMPLETED**
- \* **KAZIA WINS US, INDIA PAXALISIB COMPOSITION PATENTS**
- \* **TRAJAN \$1.3m US PAYCHECK LOAN FORGIVEN**
- \* **JENCAY CAPITAL TAKES 5.3% OF BLUECHIIP**
- \* **PERENNIAL TAKES 12% OF MEDADVISOR**

## MARKET REPORT

The Australian stock market fell 0.32 percent on Thursday June 24, 2021, with the ASX200 down 23.2 points to 7,275.3 points.

Twenty of the Biotech Daily Top 40 stocks were up, 17 fell, two traded unchanged and one was untraded. All three Big Caps fell.

Resonance was the best, up two cents or 13.3 percent to 17 cents, with 133,972 shares traded. Patry's climbed 12 percent; Nova Eye rose 8.6 percent; Pro Medicus was up 6.9 percent; Impedimed, Imugene, Neuren and Starpharma improved five percent or more; Uscom and Cyclopharm were up three percent or more; Telix and Volpara rose more than two percent; Clinuvel, Opthea, Pharmaxis, Polynovo and Universal Biosensors were up more than one percent; with Immutep, Kazia and Nanosonics up by less than one percent.

Prescient led the falls, down 2.5 cents or 11.1 percent to 20 cents, with 21.1 million shares traded. Next Science and Oncosil lost five percent or more; Optiscan fell 4.2 percent; Actinogen and Alterity were down more than three percent; Amplia, Avita, CSL, Cynata, Dimerix, Orthocell and Proteomics shed more than two percent; Cochlear, LBT and Paradigm were down one percent or more; with Genetic Signatures, Medical Developments, Mesoblast and Resmed down by less than one percent.

## PATRYS

Patrys has told the ASX that it cannot explain a 20.6 percent share price rise prior to publication of an embargoed journal article.

Last week, Patrys said that pre-clinical data for its deoxymab antibody PAT-DX1 showed its ability to cross the blood-brain barrier and inhibit growth of brain cancer and was published in the Journal of Clinical Investigation - Insight (BD: Jun 16, 2021).

Last year, Patrys said that research at the New Haven, Connecticut-based Yale School of Medicine showed that PAT-DX-NP was able to cross the blood-brain barrier and target triple-negative breast cancer brain metastases in mice (BD: Mar 2, 2020).

In its query, the ASX said the company's share price rose 20.6 percent from 3.4 cents on June 11 to 4.1 cents on June 15, and on June 16, 2021 rose to 5.0 cents and closed at 3.9 cents and noted a significant increase in the volume of securities traded on both days. The ASX noted Listing rule 3.1 which "requires a listed entity to immediately give ASX any information" considered material, and its guidance note on confidentiality: "even though an entity may consider information to be confidential and its disclosure to be a breach of confidence, if it is in fact disclosed by those who know it, then it ceases to be confidential."

Patrys said journal guidelines were strict and "breaking of an embargo can lead to withdrawal of publication", the embargo was lifted at 2am (AEST) on June 16, it was aware of the publication at about 6.30am and made the release at 9.16am.

Patrys said prior to publication, the information was "confidential, insufficiently definite to warrant disclosure and incomplete as publication in the Journal was not certain".

The company said it confirmed its compliance with the Listing Rules.

Patrys rose a further 0.6 cents or 12 percent to 5.6 cents with 148.5 million shares traded.

## BLUECHIIP

Bluechiip says Labcon has agreed to pay \$US1.6 million (\$A2.1 million) as part of the mutually beneficial dispute resolution and the two have a new supply agreement.

Bluechiip said the matter against the Petaluma, California-based Labcon was filed last year in the US District Court at the Northern District of California (BD: Jul 16, 2020).

The company said that Labcon would pay \$US850,000 in cash and return \$US750,000 worth of its "delta" identification tags and products previously sold to, and paid for, by Labcon which would be re-purposed or incorporated into its new products.

The company said it has a new supply agreement with Labcon for its Bluechiip-enabled consumables, readers, and software and would provide Labcon a credit of up to \$US1,350,000 on sales.

Bluechiip was up 0.6 cents or 19.35 percent to 3.7 cents with 14.05 million shares traded.

## NEXT SCIENCE

Next Science says Zimmer Inc has filed a complaint over commercial exclusivity rights to Xperience in the US District Court at the Northern District of Indiana.

Next Science said the Warsaw, Indiana-based Zimmer Inc alleged it had global commercial exclusivity rights over Xperience no rinse antimicrobial solution.

The company said it denied the allegations but has agreed to open negotiations with Zimmer for commercialization and distribution rights to its Xperience.

Next Science said that if the negotiations failed it intended to "vigorously defend the complaint if and when it is served" on the company while Zimmer Inc indicated that it would not serve the complaint, pending the outcome of the negotiations.

Next Science fell 8.5 cents or 5.5 percent to \$1.47.

### [PRESCIENT THERAPEUTICS](#)

Prescient says it has completed the manufacturing and delivery of components of its Omnicar platform for chimeric antigen receptor T-cell (CAR-T) therapies.

Prescient said an unnamed US antibody manufacturer has produced binders against a variety of cancer targets including chronic lymphocytic leukemia-1, CD33, human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor variant III (EGFR vIII).

The company said it has received lentiviral vectors that would be used to produce Car-T cells and both the binders and lentiviral vectors had been delivered to Melbourne's Peter MacCallum Cancer Centre for construct testing and in-vitro and in-vivo development.

Prescient managing director Steven Yatomi-Clarke said, "demonstrating that novel components can be manufactured is a crucial milestone in the development of an innovative next-generation CAR platform like Omnicar".

"Successfully producing binders ... will enable our research team to produce CAR-T cells for our three in-house programs," Mr Yatomi-Clarke said.

"Prescient's research team at the [Peter MacCallum Cancer Centre] has completed all the preparatory work in parallel and the delivery of the binders and vectors now enables the team to progress the development of our in-house next-generation cell therapies," Mr Yatomi-Clarke said.

Prescient fell 2.5 cents or 11.1 percent to 20 cents with 21.1 million shares traded.

### [KAZIA THERAPEUTICS](#)

Kazia says that the US and India patent agencies have granted patent protection for the manufacturing process of paxalisib for glioblastoma.

Kazia said that the patent, titled 'Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer', would protect its intellectual property until 2036.

The company said its existing patent for the composition of matter that covered the chemical structure of Paxalisib which was expected to expire in 2031, was "likely to be eligible for a five-year patent term extension in key territories".

Kazia said patent protection for Paxalisib had been granted in Australia, with a patent requests pending in the European Union, China, and Canada.

Kazia was up one cent or 0.8 percent to \$1.31.

### [TRAJAN GROUP HOLDINGS](#)

Trajan says the \$US960,000 (\$A1,267,372) Paycheck Protection Program loan has been forgiven by the US Government.

Trajan said the loan was under the Coronavirus Aid, Relief, and Economic Security (Cares) Act and the full liability amount would be reversed and added as a non-operating income to its year to 2021 annual accounts.

Trajan chief operating officer Stephen Tomisich said that the Paycheck Protection Program "provided the necessary support for Trajan in 2020 that allowed us to maintain our US team and support our customers during the most stressed periods caused by the pandemic."

Trajan was up two cents or 0.9 percent to \$2.35.

### BLUECHIIP

Jencay Capital says it has become a substantial shareholder in Bluechiip with 31,591,370 shares or 5.28 percent of the company.

The Alexandria, New South Wales-based Jencay Capital said between May 28 and June 21, 2021 it bought 1,959,909 shares for \$60,049 or an average price of 3.06 cents a share.

Jencay Capital said his shares were held by JP Morgan Nominees Australia.

### MEDADVISOR

Perennial Value Management says it has increased its substantial share-holding in Medadvisor from 42,509,133 shares (11.27%) to 46,366,881 shares (12.29%).

Sydney's Perennial said that it bought the shares between May 12 and June 22, 2021 with the single largest purchase 9,910,186 shares for \$2,815,484 or 28.4 cents a share.

Medadvisor was unchanged at 30 cents.